Kentaro Sumida

Tumor-infiltrating IL-17-producing γδ T cells support the progression of tumor by promoting angiogenesis

Based on the evidence that IL‐17 is a key cytokine involved in various inflammatory diseases, we explored the critical role of IL‐17‐producing γδ T cells for tumor development in tumor‐bearing mouse model. IL‐17−/− mice exhibited a significant reduction of tumor growth, concomitantly with the decrease of vascular density at lesion area, indicating a pro‐tumor property of IL‐17. Among tumor‐infiltrating lymphocytes (TIL), γδ T cells were the major cellular source of IL‐17. Analysis of TCR repertoires in TIL‐γδ T cells showed that circulating γδ T cells, but not skin resident Vγ5+γδ T cells, produced IL‐17. Neutralizing antibodies against IL‐23, IL‐6, and TGF‐β, which were produced within the tumor microenvironment, inhibited the induction of IL‐17‐producing γδ T cells. IL‐17 production by tumor‐infiltrating γδ T cells was blocked by anti‐γδTCR or anti‐NKG2D antibodies, indicating that these ligands, expressed within the tumor microenvironment, are involved in γδ T‐cell activation. The IL‐17‐producing TIL‐γδ T cells exhibited reduced levels of perforin mRNA expression, but increased levels of COX‐2 mRNA expression. Together, our findings support the novel concept that IL‐17‐producing γδ T cells, generated in response to tumor microenvironment, act as tumor‐promoting cells by inducing angiogenesis.

Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses

CD11b+Gr‐1+ immature myeloid cells (ImCs), which are abnormally increased in tumor‐bearing mice, were classified into three different subsets according to their phenotypic and morphological characteristics: Gr‐1low F4/80+ macrophages (MΦ‐ImCs), Gr‐1mid stab neutrophils (Neutstab‐ImCs), and Gr‐1high segmented neutrophils (Neutseg‐ImCs). In the spleen, only MΦ‐ImCs but not Neutstab‐ImCs and Neutseg‐ImCs exhibited a significant immunosuppressive activity in MLR. In contrast, tumor‐infiltrating leukocytes (TILs) contained only two ImC subsets, MΦ‐ImCs and Neutseg‐ImC, both of which exhibited stronger inhibitory activity against T cells compared with spleen‐MΦ‐ImCs. Thus, we concluded that tumor‐infiltrating MΦ‐ImCs and Neutseg‐ImCs were fully differentiated myeloid‐derived suppressor cells (MDSCs) with stronger T‐cell inhibitory activity. Indeed, spleen MΦ‐ImCs were converted into stronger MΦ‐MDSCs by tumor‐derived factor (TDF). Moreover, both spleen Neutstab‐ImCs and Neutseg‐ImCs differentiated into Neutseg‐MDSCs with suppressive activity after culture with TDF. We first demonstrated that administration of anti‐IL‐6R mAb could downregulate the accumulation of MΦ‐MDSCs and Neutseg‐MDSCs in tumor‐bearing mice. The elimination of those MDSCs caused subsequent enhancement of antitumor T‐cell responses, including IFN‐γ‐production. The therapeutic effect of anti‐IL‐6R mAb was further enhanced by combination with gemcitabine (GEM). Thus, we propose that anti‐IL‐6R mAb could become a novel tool for the downmodulation of MDSCs to enhance antitumor T‐cell responses in tumor‐bearing hosts.

The Key Role of IL-6–Arginase Cascade for Inducing Dendritic Cell–Dependent CD4+ T Cell Dysfunction in Tumor-Bearing Mice

Evaluation of immune dysfunction during the tumor-bearing state is a critical issue in combating cancer. In this study, we initially found that IL-6, one of the cachectic factors, suppressed CD4+ T cell–mediated immunity through downregulation of MHC class II by enhanced arginase activity of dendritic cells (DC) in tumor-bearing mice. We demonstrated that administration of Ab against IL-6R (anti–IL-6R mAb) greatly enhanced T cell responses and inhibited the growth of tumor in vivo. We also found that IL-6 upregulated the expression of arginase-1 and arginase activity of DC in vitro. Tumor-infiltrating CD11c+ DC exhibited upregulated mRNA expression of arginase-1 but reduced expression of MHC class II in parallel with the increase in serum IL-6 levels at the late stage in tumor-bearing hosts. However, the administration of anti–IL-6R mAb into tumor-bearing mice inhibited both the downmodulation of MHC class II and the upregulation of arginase-1 mRNA levels in DC. Furthermore, we noted that Nω-hydroxy-L-arginine or L-arginine, an arginase-1 inhibitor, blocked the reduction in MHC class II levels on CD11c+ DC during the tumor-bearing state. Finally, we demonstrated that the administration of Nω-hydroxy-L-arginine at the peritumor site significantly enhanced CD4+ T cell responses and inhibited tumor growth. Thus, IL-6–mediated arginase activation and the subsequent reduction in MHC class II expression on DC appeared to be critical mechanisms for inducing dysfunction of the immune system in the tumor-bearing state. Blockade of the IL-6–arginase cascade is a promising tool to overcome the dysfunction of antitumor immunity in tumor-bearing hosts.

IFN-γ-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model

3-Methylcholanthrene (MCA)-induced sarcomas have been used as conventional tools for investigating immunosurveillance against tumor development. However, MCA-induced sarcoma is not always an ideal model for the study of the human cancer system because carcinomas and not sarcomas are the dominant types of human cancers. To resolve this problem, we established a novel and simple method to induce mouse squamous cell carcinomas (SCCs). As well known, the subcutaneous injection of MCA caused the formation of sarcomas at 100% incidence. However, we here first succeeded at inducing SCC at 60% of incidence within 2 months by a single intra-dermal injection of MCA. Using this primary SCC model, we demonstrated the critical role of interferon (IFN)-gamma-dependent type 1 immunity in immunosurveillance against SCC from the following results: (i) The incidence of SCC was accelerated in IFN-gamma-deficient mice compared with that in wild-type mice; (ii) In vivo injection of CpG-oligodeoxynucleotides (CpG-ODN) caused a marked reduction in the incidence of SCC in parallel with the activation of type 1-dependent antitumor immunity and (iii) The antitumor activity of CpG-ODN was significantly decreased in IFN-gamma-deficient mice. Thus, our established MCA-induced mouse SCC model could be a powerful tool for evaluating immunosurveillance mechanisms during the development of SCC and might result in a novel strategy to address immunosurveillance mechanisms of human cancer.

IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells.

Immunosuppression in tumor microenvironments critically affects the success of cancer immunotherapy. Here, we focused on the role of interleukin (IL)-6/signal transducer and activator of transcription (STAT3) signaling cascade in immune regulation by human dendritic cells (DCs). IL-6-conditioned monocyte-derived DCs (MoDCs) impaired the presenting ability of cancer-related antigens. Interferon (IFN)-γ production attenuated by CD4+ T cells co-cultured with IL-6-conditioned MoDCs corresponded with decreased DC IL-12p70 production. Human leukocyte antigen (HLA)-DR and CD86 expression was significantly reduced in CD11b+CD11c+ cells obtained from peripheral blood mononuclear cells (PBMCs) of healthy donors by IL-6 treatment and was STAT3 dependent. Arginase-1 (ARG1), lysosomal protease, cathepsin L (CTSL), and cyclooxygenase-2 (COX2) were involved in the reduction of surface HLA-DR expression. Gene expressions of ARG1, CTSL, COX2, and IL6 were higher in tumor-infiltrating CD11b+CD11c+ cells compared with PBMCs isolated from colorectal cancer patients. Expression of surface HLA-DR and CD86 on CD11b+CD11c+ cells was down-regulated, and T cell-stimulating ability was attenuated compared with PBMCs, suggesting that an immunosuppressive phenotype might be induced by IL-6, ARG1, CTSL, and COX2 in tumor sites of colorectal cancer patients. There was a relationship between HLA-DR expression levels in tumor tissues and the size of CD4+ T and CD8+ T cell compartments. Our findings indicate that IL-6 causes a dysfunction in human DCs that activates cancer antigen-specific Th cells, suggesting that blocking the IL-6/STAT3 signaling pathway might be a promising strategy to improve cancer immunotherapy.

Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy

Conquering immunosuppression in tumor microenvironments is crucial for effective cancer immunotherapy. It is well known that interleukin (IL)‐6, a pleiotropic cytokine, is produced in the tumor‐bearing state. In the present study, we investigated the precise effects of IL‐6 on antitumor immunity and the subsequent tumorigenesis in tumor‐bearing hosts. CT26 cells, a murine colon cancer cell line, were intradermally injected into wild‐type and IL‐6‐deficient mice. As a result, we found that tumor growth was decreased significantly in IL‐6‐deficient mice compared with wild‐type mice and the reduction was abrogated by depletion of CD8+ T cells. We further evaluated the immune status of tumor microenvironments and confirmed that mature dendritic cells, helper T cells and cytotoxic T cells were highly accumulated in tumor sites under the IL‐6‐deficient condition. In addition, higher numbers of interferon (IFN)‐γ‐producing T cells were present in the tumor tissues of IL‐6‐deficient mice compared with wild‐type mice. Surface expression levels of programmed death‐ligand 1 (PD‐L1) and MHC class I on CT26 cells were enhanced under the IL‐6‐deficient condition in vivo and by IFN‐γ stimulation in vitro. Finally, we confirmed that in vivo injection of an anti‐PD‐L1 antibody or a Toll‐like receptor 3 ligand, polyinosinic‐polycytidylic acid, effectively inhibited tumorigenesis under the IL‐6‐deficient condition. Based on these findings, we speculate that a lack of IL‐6 produced in tumor‐bearing host augments induction of antitumor effector T cells and inhibits tumorigenesis in vivo, suggesting that IL‐6 signaling may be a promising target for the development of effective cancer immunotherapies.

IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signalling pathway

Myeloid-derived suppressor cells (MDSCs) are immune negative regulators in the tumour microenvironment. Interleukin (IL)-11, a member of IL-6 family cytokines, functions through the unique receptor IL-11 receptor α coupled with the common signal transducer gp130. IL-11-gp130 signalling causes activation of the JAK/STAT3 pathway. IL-11 is highly upregulated in many types of cancers and one of the most important cytokines during tumourigenesis and metastasis. However, the precise effect of IL-11 on differentiation into MDSCs is still unknown. Here, we found that CD11b+CD14+ monocytic MDSCs were generated from peripheral blood mononuclear cells (PBMCs) of healthy donors in the presence of IL-11. IL-11-conditioned PBMCs induced higher expression of immunosuppressive molecules such as arginase-1. A reduction of T-cell proliferation was observed when MDSCs generated in the presence of IL-11 were co-cultured with CD3/CD28-stimulated, autologous T cells of healthy donors. Culture of normal PBMCs with IL-11 led to STAT3 phosphorylation and differentiation into MDSCs via STAT3 activation. We confirmed expressions of both IL-11 and phosphorylated STAT3 in tumour tissues of colorectal cancer patients. These findings suggest that monocytic MDSCs may be induced by IL-11 in the tumour microenvironment. Thus, IL-11-mediated regulation in functional differentiation of MDSCs may serve as a possible target for cancer immunotherapy.

Neuropeptide signaling through neurokinin-1 and neurokinin-2 receptors augments antigen presentation by human dendritic cells.

Title Neuropeptide signaling through neurokinin-1 and neurokinin-2 receptors augments antigen presentation by human dendritic cells Author(s) Ohtake, Junya; Kaneumi, Shun; Tanino, Mishie; Kishikawa, Takuto; Terada, Satoshi; Sumida, Kentaro; Masuko, Kazutaka; Ohno, Yosuke; Kita, Toshiyuki; Iwabuchi, Sadahiro; Shinohara, Toshiya; Tanino, Yoshinori; Takemura, Tamiko; Tanaka, Shinya; Kobayashi, Hiroya; Kitamura, Hidemitsu Citation Journal of Allergy and Clinical Immunology, 136(6): 1690-1694

Abstract 3615: IL-6/STAT3-dependent immunosuppressive function of tumor-infiltrating dendritic cells in colorectal cancer

Introduction Immunosuppression in tumor microenvironments is one of the critical issues for cancer immunotherapy. To develop more effective treatment, it is essential to overcome the dysfunction of immunity in cancer patients. Recently, it has been demonstrated that myeloid derived suppressor cells (MDSCs) have crucial roles for such immunosuppression. In the current reports, it was indicated that activation of STAT3 was required for immunosuppressive function of human MDSCs. In this study, we focused on IL-6/STAT3-signaling pathway in human monocyte-derived dendritic cells (DCs), and investigated the effects of IL-6 on antigen-presenting ability of DCs. Materials and Methods Tumor-infiltrating myeloid cells and PBMCs were collected from specimen of patients with colorectal cancers. Surface molecules , such as HLA-DR, of the cells were investigated by flowcytometry. Then, the surface molecules of monocyte-derived DCs from healthy volunteers were evaluated after the stimulation with IL-6 in vitro. IL-6-treated DCs were co-cultured with autologous T cells stimulated by using anti-CD3 antibody and cytokine production levels were investigated by ELISA. MAGE-A4-specific CD4+ T cells were generated from PBMCs ofhealthy healthy volunteers in vitro and co-cultured with IL-6-pretreated DCs in the presence of MAGE-A4 antigen. Cytokine production by antigen specific T cells were measured by ELISA. Results In this study, we found that expression levels of HLA-DR and CD86 are down regulated in tumor infiltrating CD11c+CD14+ DCs compared with peripheral monocytes. In addition, we confirmed that HLA-DR and CD86 expressions were significantly reduced by IL-6 treatment of CD11c+CD14+ DCs in vitro. The reduction of HLA-DR and CD86 expression levels were remarkably blocked in the presence of STAT3 inhibitor. IFN-γ production by T cells after TCR-stimulation was suppressed in the presence of IL-6-treated DCs compared with control DCs. Moreover, activation of MAGE-A4 antigen-specific CD4+ T cells were remarkably reduced by IL-6-treatment of DCs. Discussion Previously, it was reported that CD14+HLA-DRlow/- cells increased in peripheral blood of cancer patients and that these cells were an important population for immunosuppression. In this study, we demonstrated that IL-6/STAT3-signaling cascade was one of the regulating factors for surface expression levels of HLA-DR on DCs. In addition, we confirmed that IL-6-treatment significantly suppressed the antigen presentation by DCs for cancer antigen-specific CD4+ T cells. Generally, MDSCs were known to induce several immunosuppressive and tumor promoting factors such as VEGF, ARG1, and COX2. We are now investigating target molecules of IL-6 for dysfunction of DCs in tumor microenvironments. Conclusion IL-6/STAT3 signaling pathway regulates immunosuppressive function of human DCs, which would be a promising target for improving the effects of cancer immunotherapy. Citation Format: Yosuke Ono, Jyunya Ohtake, Shun Kaneumi, Kazutaka Masuko, Kentaro Sumida, Takuto Kishikawa, Satoshi Terada, Toshiyuki Kita, Norihiko Takahashi, Akinobu Taketomi, Hidemitsu Kitamura. IL-6/STAT3-dependent immunosuppressive function of tumor-infiltrating dendritic cells in colorectal cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3615. doi:10.1158/1538-7445.AM2014-3615

Regulation of Antigen Presentation by Dendritic Cells and Its Application to Cancer Immunotherapy

Dendritic cells (DCs) are one of the most powerful antigen-presenting cells and play a crucial role in bridging between innate and acquired immunity. Cancer antigens or the long peptides are engulfed by DCs, digested into helper and killer epitope peptides, transported to the cell surface, and presented to CD4+ and CD8+ T cells through major histocompatibility complex (MHC) class II and MHC class I to induce effector T helper cells and cytotoxic killer T cells, respectively. In addition, DCs produce type 1 cytokines such as interleukin (IL)-12 and interferon (IFN)-α/-β to facilitate differentiation of naive T cells into effector T cells and activation of memory T cells. Therefore, proper regulation of DC function is essential for induction and augmentation of anti-tumor immunity in cancer patients. Generally, DCs are immediately activated by various maturation signals including Toll-like-receptor (TLR) ligands, type 1 cytokines, and CD40/40L interaction. On the other hand, IL-6 produced in tumor microenvironments caused dysfunction of DCs through reduction of MHC class II expression and IL-12 production. It has recently been reported that zinc transporter-mediated intracellular zinc levels and neuropeptide signaling through the receptors are involved in the regulation of the antigen-presenting function of DCs in type 1 immune responses, including TLR-mediated inflammatory response. In this chapter, we report on regulation of the antigen-presenting function and the potential benefit of DC-mediated cancer immunotherapy.